How poorly did Lexicon, Orexigen, and Ariad stocks perform this week? Bad enough to be the three worst health-care stocks in the land.
Celldex's offering puts acquisition/partnership rumors by the likes of Roche, Amgen, or Alexion on the back burner. It also raises significant questions prior to a major data release. Does it change the outlook for the Celldex's stock?
Favorable approval news from Europe and Japan, a small-cap biotech buying drug rights, and positive preclinical results to potentially treat a deadly infectious disease are this week's must-know biotech stories.
Cost sharing among drug developers is helping keep pipelines fresh at Isis Pharmaceuticals. But translating those pipelines into approved therapies is necessary for Isis to turn profitable.
Both Biogen and Amgen are fighting competition with new drugs with blockbuster potential, but is one a better buy than the other?
These five drugs demonstrated a lot of promise heading into 2013, but all of them fell flat on their face in some form or another.
In a situation reminicent of Elan and Biogen Idec's Tysabri, Ariad Pharmaceuticals needs to get Iclusig back on the market. How that'll affect competing leukemia drugs from Novartis, Bristol-Myers Squibb, and Pfizer remains to be seen.
Will Celgene's efforts to diversify its drug portfolio into inflammatory diseases with apremilast pay off?
Will Pfizer’s oncology business finally help the company grow its top line again?
A meta-analysis of nearly 800 patients over a two-year period looks at the advantages of diet and exercise versus surgery and comes to an interesting conclusion. See where your big market opportunity as an investor could lie in the fight against obesity.